Factors regulating the differentiation of sheep subcutaneous and abdominal (omental or perirenal) preadipocytes from foetal lambs, suckling lambs and fattening sheep have been investigated using a serum-free cell culture system. Differentiation was assessed by changes in the activity of the enzyme glycerol 3-phosphate dehydrogenase. Insulin or IGF-I was essential for differentiation. Dexamethasone, a lipid supplement (Excyte) and the thiazolidinedione, rosiglitazone (BRL 49653) (a peroxisome proliferator-activated receptor-(PPAR-) agonist) all enhanced preadipocyte differentiation, whereas fibroblast growth factor and GH were inhibitory. The most effective combination was insulin, triiodothyronine, dexamethasone and rosiglitazone. Under suboptimal conditions, preadipocytes from fattening sheep differentiated less well than cells from suckling and foetal lambs. Also, under suboptimal conditions, abdominal preadipocytes did not differentiate as well as subcutaneous preadipocytes. However, age and depot differences were minimised when cells were cultured with insulin, triiodothyronine, rosiglitazone and either dexamethasone or lipid. The results suggest that variation in the ability to produce the natural ligand for PPAR-contributes to depot-and age-specific differences in the ability of preadipocytes to differentiate.
Introduction
In mammals, adipose tissue occurs as a number of depots, some located in the abdominal cavity (e.g. omental), some under the skin (subcutaneous depots), some within the musculature (inter-and intramuscular depots) (Pond 1992) . Accretion of adipose tissue occurs through both hypertrophy of adipocytes (due to lipid accumulation) and adipocyte hyperplasia. Adipocytes do not divide, but rather are formed from precursor cells which proliferate and differentiate into mature adipocytes (Ailhaud et al. 1992 , Flint & Vernon 1993 , Grégoire et al. 1998 . These precursor cells are found in the stromal-vascular fraction of adipose tissue, and can be induced to proliferate and differentiate in vitro in chemically defined media; this has allowed investigation of the factors which regulate the production of adipocytes in a number of species including humans, rodents, ruminants, pigs and birds (Ailhaud et al. 1992 , Ramsay et al. 1992 , Flint & Vernon 1993 , Butterwith 1994 , Grégoire et al. 1998 revealing key roles for insulin or insulin-like growth factor-I (IGF-I), and also glucocorticoids and triiodothyronine (T 3 ) in some species.
Understanding of the basis of adipogenesis at a molecular level has been greatly facilitated by the development of various cell lines, mostly of murine origin, which will differentiate into adipose-like cells in vitro and in vivo (Hwang et al. 1997 , Grégoire et al. 1998 . Such studies have identified the key role of the transcription factor, PPAR-(peroxisome proliferatoractivated receptor-), in adipogenesis. PPAR-is activated by arachidonic acid metabolites such as 15-deoxy-12,14 -PGJ2 and also thiazolidinedione drugs such as rosiglitazone (BRL 49653) (Spiegelman 1998) . Despite these observations with cell lines, little is known about the role of PPAR-in differentiation of primary cultures of preadipocytes.
In sheep there is very active hyperplasia during foetal growth, resulting in about 10 9 subcutaneous and about 5 10 8 omental and also perirenal adipocytes at birth, and there is further hyperplasia of subcutaneous, and, to a lesser extent, abdominal adipocytes during the suckling period (Vernon 1986) . During the fattening phase of development there is again hyperplasia of subcutaneous adipocytes, but little or no hyperplasia of omental and perirenal adipocytes (Broad et al. 1980 , Vernon 1986 ). The basis of these depot-specific differences in hyperplasia has not been resolved. However, cell culture studies have shown that preadipocytes from different depots from rats (Björntorp et al. 1980 , Deslex et al. 1987 , Wiederer & Löffler 1987 , Sztalryd et al. 1989 , Grégoire et al. 1990 , Kirkland et al. 1990 , Sztalryd & Faust 1990 , Wabitsch et al. 1996b ) and humans (Hauner et al. 1988 , Hauner & Entenmann 1991 can vary in their ability to differentiate in vitro under identical conditions. This suggests that one factor contributing to differential hyperplastic growth of different adipose tissue depots is an intrinsic difference in their preadipocytes. Other factors, such as differences in the production of adipogenic paracrine factors in different depots (Lau et al. 1990 , Ailhaud et al. 1991 may also be involved.
Although intrinsic differences in the ability of preadipocytes from different depots to differentiate are apparent, studies to date have not demonstrated if preadipocytes vary in response to a single, several or all adipogenic factors. In the present study we have further investigated the effects of various factors, including the PPARagonist, rosiglitazone, on differentiation of subcutaneous and abdominal adipocytes from sheep of different ages (foetal, suckling, fattening). We find that, while subcutaneous preadipocytes have a greater proclivity to differentiate than abdominal preadipocytes under some conditions, differences are markedly diminished when rosiglitazone is included in the medium. This suggests that differences in the ability to produce the natural ligands of PPAR-may contribute to the depot-specific ability of preadipocytes to differentiate.
Material and Methods

Materials
Dulbecco's modified Eagle's medium (DMEM-F12 medium), Medium 199 (M199), Hanks' balanced salt solution (HBSS), new-born calf serum, penicillin, streptomycin and -glutamine were from Gibco-BRL, Paisley, UK. Collagenase type I, BSA, insulin, T 3 , dexamethasone, fibroblast growth factor (FGF), bezafibrate, dihydroxyacetone phosphate and NADH were from Sigma Chemical Co., Poole, Dorset, UK. IGF-I was from Bachem, Safron Walden, Essex, UK. Excyte III (a lipid supplement) was from Bayer, CA, USA. NP-40 (protein grade) was from Calbiochem, Nottingham, UK. WY 14,643 was from Affinity (Biomol) Research Products Ltd, Exeter, UK. Rosiglitazone was a gift from Dr J Holder (SmithKline Beecham, Welwyn, Herts, UK); recombinant bovine growth hormone (GH) was a gift from Dr R Hoffman (Monsanto Co., Protiva Division, St Louis, MO, USA); rabbit anti-bovine GH serum was a gift from Dr D J Flint (Hannah Research Institute, Ayr, UK).
Animals
Finn Dorset-Horn cross-bred sheep were used. Suckling lambs were about 1 month old and were left with their mothers until slaughter. Fattening sheep were 6-to 8-month-old castrated males; pregnant sheep were 4-6 years old and about 115 days pregnant; fattening sheep and pregnant sheep were freely fed on hay plus a cereal mix (400 g/day and 800 g/day respectively). Sheep were anaesthetised by intrajugular injection of 10-30 ml Sagatal (pentobarbitone), depending on animal size, at 0930 h and exsanguinated. Pieces of subcutaneous adipose tissue from the flank and from either omental or perirenal adipose tissue were removed aseptically. Adipose tissue was placed into sterile saline (0·15 M NaCl, 37 C).
Cell culture
Tissue was sliced and cells were released by collagenase digestion in Krebs-Ringer bicarbonate buffer (1·22 mM CaCl 2 ) (Krebs & Henseleit 1933) containing 25 mM Hepes (pH 7·4), 5·5 mM glucose, 2 mM acetate, 2 mg/ml collagenase and 40 mg/ml BSA for 1 h at 37 C with constant agitation. The digested tissue was filtered through a nylon mesh screen to separate cells from undigested tissue fragments and debris. The filtrate was collected in a sterile 50 ml centrifuge tube and the top layer containing the mature adipocytes was removed by aspiration and discarded. The remaining infranatant was centrifuged at 1400 g for 5 min at room temperature. The pellet was washed twice by centrifugation (1400 g, 5 min) with HBSS. The final pellet was resuspended in HBSS and filtered through a 20 µm mesh screen. The cells were counted using a haemocytometer, centrifuged at 1400 g for 5 min, resuspended in medium consisting of M199 supplemented with 20% new-born calf serum, 2 mM acetate, 2 mM -glutamine, penicillin (100 U/ml) and streptomycin (100 µg/ml) and seeded in 60 mm culture dishes at a density of approximately 2500 cells/cm 2 . The cells were incubated at 37 C in 5% CO 2 in air. After 24 h, attached cells were washed twice with HBSS and fresh medium was added. Culture medium was changed every second day, allowing the cells to proliferate to confluence (about 10 days). Then the cells were exposed to differentiation-induction media: DMEM-F12 medium plus penicillin (100 U/ml) and streptomycin (100 µg/ml) supplemented with combinations of T 3 (2 nM), insulin (1·6 µg/ml or 5 ng/ml), dexamethasone (10 nM), IGF-I (1 µg/ml or 5 ng/ml), FGF (100 ng/ml), GH (45 ng/ml), a lipid supplement (Excyte III, 10 µl/ml) and rosiglitazone (100 nM). Hormones and other additions were present for the whole of the differentiation period, unless otherwise stated in the text. Differentiation media were replaced with fresh media twice during the differentiation period. In two experiments, the proliferation medium was prepared using new-born calf serum which had been depleted of GH (Yarwood et al. 1998 ). This was prepared by incubating new-born calf serum with rabbit anti-bovine GH serum (1:1000 dilution) for 24 h at room temperature. Antiserum to rabbit IgG was then added to a final dilution of 1:10. After 4 h the precipitate was pelleted by centrifugation at 3000 g for 30 min and the supernatant (GHdepleted calf serum) carefully removed.
Glycerol 3-phosphate dehydrogenase (GPDH) activity
Differentiation of the cells was monitored by the activity of the marker enzyme, GPDH (EC 1·1·1·8). Briefly, cells were washed twice with ice-cold PBS; 0·5 ml of assay buffer (100 mM triethanolamine, 2·5 mM EDTA, 0·1 mM mercaptoethanol, 0·5% NP40) was added and the cells were scraped from the wells mechanically. The cell suspension was transferred to a 1·5 ml centrifuge tube and lysed by drawing the suspension into a 1 ml syringe fitted with a 27 gauge needle. The lysate was rotated for 15 min at 4 C and then centrifuged at 14 000 g in a microfuge for 10 min at 4 C. The supernatant was removed and immediately assayed for GPDH activity as described by Wise & Green (1979) . Except for time-course studies, GPDH activity was measured on the 10th day of differentiation.
Protein determination
Protein content was determined by the Bradford (1976) method, using BSA as standard.
Statistical analysis
Data were analysed by ANOVA or restricted maximum likelihood (REML) (Patterson & Thompson 1971) ; depending on the experiment, the factors comprised treatment, adipose tissue depot, age of animal and their interactions. Results are given as means with an ... value from the ANOVA or REML analysis. Each value contributing to a mean came from a different sheep.
Results
Differentiation of preadipocytes was assessed by changes in the activity of the marker enzyme GPDH/mg protein and by the appearance of lipid droplets within the cells. Preparatory studies, in which differentiation was induced by insulin, T 3 and lipid, showed that droplets began to appear by day 3 of differentiation and reached a maximum by about day 9 of differentiation, which was maintained for a further 3 days (results not shown). Similarly, GPDH levels also increased during the first week of differentiation, reaching maximum levels between days 9 and 12 (results not shown).
Factors regulating differentiation
An initial study using lipid, T 3 and insulin showed that omission of insulin from the culture medium resulted in little or no differentiation (Adams et al. 1996) . Further studies showed that the high concentration (1·6 µg/ml) of insulin used routinely in the cultures could be replaced by either a lower (5 ng/ml) concentration of insulin or 1·0 µg/ml or 5 ng/ml of IGF-I (results not shown). In this and subsequent studies, GPDH activity of control subcutaneous and omental preadipocytes maintained in proliferation medium for 10 days was 1-2 nmol/min per mg protein.
The addition of lipid increased GPDH activity/mg protein (Fig. 1) . Analysis of the pooled data (all ages and depots) of Table 1 showed a highly significant (P<0·01) increase in GPDH activity due to lipid. The PPAR-agonist rosiglitagone (Krey et al. 1997) increased (P<0·001) GPDH activity of preadipocytes (analysis of pooled data from all depots and all ages) (Table 1, Fig. 1 ). Maximum effect was achieved with a concentration of Figure 1 Changes in GPDH activity during differentiation of (a) subcutaneous and (b) omental preadipocytes from fattening sheep. Differentiation was induced by adding: insulin (1·6 g) and T 3 (2 nM) (); insulin, T 3 and lipid 10 l/ml) (); insulin, T 3 and rosiglitazone (100 nM) (); insulin, T 3 , lipid and rosiglitazone (). Results are means of three observations each from a different fattening sheep. Results analysed by ANOVA; S.E.D. 19·3 and 7·3 respectively for subcutaneous and omental preadipocytes. 100 nM rosiglitazone (Fig. 2a) . WY 14,643 at 100 µM, and 100 µM bezafibrate, PPAR-and PPAR-agonists (Krey et al. 1997) , also increased GPDH activity (Fig. 2b ), but to a lesser extent than rosiglitazone (Fig. 2a) , and effects of WY 14,643 were apparent only in omental preadipocytes (Fig. 2b) . Analysis of pooled data for all depots and ages (Table 1) showed that rosiglitazone was a better (P<0·001) stimulant of differentiation than lipid and that a combination of the two was no better than rosiglitazone alone.
Dexamethasone increased (P<0·001) differentiation (Table 2) , maximum effects being achieved with 1 nM (results not shown). Analysis of pooled data for both ages and depots (Table 2) showed that dexamethasone was as effective as rosiglitazone in stimulating differentiation, and the combination of the two was more effective (P<0·001) than either alone.
Addition of FGF decreased differentiation (Table 3) . Addition of GH decreased (P<0·05) GPDH activity/mg protein when added for the whole period of differentiation; when added for the first 3 days of differentiation, GH induced an intermediate GPDH activity (Table 3) . Two experiments were performed in which the new-born calf serum used during the proliferation phase was immunodepleted of GH; this had no effect on the subsequent ability of subcutaneous preadipocytes to differentiate in the presence of insulin, T 3 and lipid (results not shown). In contrast, 3T3-F442A cells allowed to proliferate in GHdepleted new-born calf serum failed to differentiate unless transiently exposed to GH (Yarwood et al. 1998) .
Addition of either rosiglitazone or dexamethasone caused a small (40%, P<0·05) increase in the amount of protein/culture well. Addition of lipid induced a greater increase in protein/well (65%, P<0·01), while the combinations of lipid and either rosiglitazone or dexamethasone increased the protein content by 150% (P<0·001) (results not shown, but from analysis of pooled data from experiments described in Tables 1 and 2 ). Addition of either FGF or GH had no effect on the protein/well (results not shown).
Age and depot effects
Analysis by REML and ANOVA of pooled data of Table 1 and of Table 2 respectively showed that, for the conditions used in each case, subcutaneous preadipocytes differentiated more than preadipocytes from abdominal depots (P<0·001, Table 1; P<0·01, Table 2 ). Furthermore, preadipocytes from foetal and suckling lambs differentiated to a similar extent, whereas preadipocytes from fattening sheep differentiated less well (P<0·001) ( Table 1) . Neither depot nor age of animal had any significant effect on the amount of protein/culture well for culture conditions used in Tables 1 and 2. Examination of results of Tables 1-3 shows some age, depot, treatment interaction. Thus for foetal subcutaneous preadipocytes, lipid and rosiglitazone, either singly or in combination, had no significant effect on GPDH activity. In contrast, omental preadipocytes from fattening sheep showed a 12-fold increase in GPDH activity when insulin plus T 3 was supplemented with lipid and rosiglitazone ( Table 1 ). The response of other preadipocytes to lipid and rosiglitazone fell between these two extremes (Table 1) . Furthermore, when insulin and T 3 alone were used to stimulate differentiation, the GPDH activity achieved with subcutaneous preadipocytes from foetal lambs was almost 30-fold greater than that achieved with omental preadipocytes from fattening sheep (Table 1) , with other preadipocytes exhibiting GPDH values between these two extremes. In contrast, when the medium was further supplemented with lipid and rosiglitazone, the highest GPDH activities achieved were less than 3-fold greater than the lowest (omental preadipocytes from fattening sheep) (Table 1) . A similar pattern of response was seen in Table 1 Effects of rosiglitazone and lipid supplementation on GPDH activity of ovine subcutaneous and adbominal (omental or perienal) preadipocytes. Differentiation was induced by the addition of insulin (1·6 g/ml) and T 3 (2 nM) with and without lipid (10 l/ml) and rosiglitazone (100 nM) as indicated. GPDH activity was determined after 10 days of differentiation. Results are means of from 4 to 14 values, each from a different animal (numbers of observations are given in parentheses) studies with dexamethasone (Table 2) , where the addition of dexamethasone with and without rosiglitazone had a much greater proportionate effect on omental preadipocytes from fattening sheep than with subcutaneous preadiopcytes from suckling lambs. Finally, Table 3 shows that response to the inhibitory effects on differentiation of FGF and GH is lacking in subcutaneous preadipocytes from foetal lambs, but is present in other preadipocytes tested. Taken together then, the various studies described in Tables 1-3 show that there is an age-depot based hierarchy in proclivity to differentiate, with subcutaneous preadipocytes from foetal and suckling lambs having the greatest tendency and omental preadipocytes from fattening sheep having the least. Furthermore, differences are greatest when a weak stimulus (insulin plus T 3 ) is used to promote differentiation and least when strong stimuli (insulin, T 3 , rosiglitazone and either lipid or dexamethasone) are used.
Discussion
The present studies show that insulin, IGF-I, dexamethasone, lipid and the PPAR-agonist, rosiglitazone promote differentiation of ovine preadipocytes. Previous studies with ovine (Broad & Ham 1983 , Casteilla et al. 1991 , Vierck et al. 1996 and bovine preadipocytes (Aso et al. 1995) have also found a high concentration of insulin or IGF-I to be essential for differentiation, and dexamethasone to enhance differentiation. Broad & Ham (1983) found a lipid supplement stimulated differentiation of ovine preadipocytes, while Björntorp et al. (1980) showed that lipid stimulated differentiation of rat preadipocytes. Broad & Ham (1983) found that FGF stimulated differentiation of ovine preadipocytes, whereas Vierck et al. (1996) found that, in the presence of insulin and dexamethasone, FGF had no effect on differentiation of ovine preadipocytes. Conflicting reports on effects of FGF on preadipocyte differentiation have also been reported for the rat (Grégoire et al. 1998) . The reason for the differences in response to FGF is not resolved. GH decreased differentiation of pig (Hausman & Martin 1989 , Hausman et al. 1992 , human (Wabitsch et al. 1995 (Wabitsch et al. , 1996a and rat (Wabitsch et al. 1996b) preadipocytes. By contrast, GH acts as a commitment factor for differentiation of several murine preadipocyte cell lines (e.g. 3T3-F442A cells) (Wabitsch et al. 1995 , Hwang et al. 1997 , Grégoire et al. 1998 . However, there is no evidence for a requirement for GH as a commitment factor for differentiation of rat or human preadipocytes in primary culture (Ailhaud et al. 1992 , Wabitsch et al. 1995 , possibly because cells are exposed to GH in vivo prior to culture and during proliferation in serum-containing media. The present study provides no evidence for GH acting as a commitment factor for sheep preadipocytes, as culture in GH-depleted serum during the proliferative phase had no effect on subsequent differentiation, while addition of GH during the first 72 h of differentiation again led to decreased GPDH activity. Rosiglitazone is a potent agonist of PPAR- (Lehmann et al. 1995 , Krey et al. 1997 ) and the dose-response curve (Fig. 2a) is consistent with it acting as a PPAR-agonist in ovine preadipocytes. The PPAR-agonist, WY 14,643 (Lehmann et al. 1995 , Krey et al. 1997 , at a concentration of 100 µM, also had a small effect on differentiation, but at this concentration it can also activate PPAR- (Lehmann et al. 1995) . Bezafibrate is a relatively specific PPARagonist (Krey et al. 1997 ) and the dose-response curve Figure 2 Changes in GPDH activity during differentiation of subcutaneous (, ) and omental (, ) preadipocytes from fattening sheep. Preadipocytes were maintained in culture with insulin (1·6 g/ml), T 3 (2 nM) and lipid (10 l/ml) plus various concentrations of (a) rosiglitazone (, ), or (b) bezafibrate (, ) or WY 14,643 (, ). Results are means of three observations, each from a different animal. Results were analysed by ANOVA; the common S.E.M. value from the ANOVA is shown for 1000 nM rosiglitazone and 100 M bezafibrate and WY 14,643.
( Fig. 2b) is consistent with PPAR-having a role in differentiation of ovine preadipocytes. PPAR-has also been proposed to be involved in differentiation of some preadipocyte cell lines, but this remains controversial (Smith 1997 , Grégoire et al. 1998 .
Although studies with preadipocyte cell lines have shown that the amount of PPAR-increases during differentiation and that agents which activate PPAR-are potent stimulators of differentiation (Grégoire et al. 1998 , Spiegelman 1998 , little is known about its role in differentiation of primary preadipocytes. Two very recent studies have shown that rosiglitazone can enhance differentiation in vitro of human (Adams et al. 1997) and bovine (Ohyama et al. 1998) preadipocytes. We now show that the effects of rosiglitazone on preadipocyte differentiation are complex and vary with depot, age of the animal and other components of the differentiation medium. Thus the effects of rosiglitazone were proportionally greater with preadipocytes from fattening sheep rather than foetal lambs and with abdominal rather than subcutaneous preadipocytes. With subcutaneous preadipocytes from suckling lambs, rosiglitazone and dexamethasone were equally effective in increasing GPDH activity and effects were not additive. In contrast, with omental preadipocytes from suckling lambs, and with preadipocytes from both subcutaneous and omental adipose tissue from fattening sheep, effects of rosiglitazone and dexamethasone on GPDH activity were additive ( Table 2 ). The basis of these differential interactions of rosiglitazone are not certain. However, dexamethasone increased the amount of PPAR-in differentiated adipocytes (Vidal-Puig et al. 1997) and in a preadipocyte cell line (Wu et al. 1996) ; a Table 2 Effects of dexamethasone and rosiglitazone on GPDH activity of preadipocytes from suckling lambs and fattening sheep. Differentiation was induced by the addition of insulin (1·6 g/ml) and T 3 (2 nM) with and without dexamethasone (10 nM) and rosiglitazone (100 nM) as indicated. GPDH activity was assayed after 10 days of differentiation. Table 3 Effects of FGF and GH on GPDH activity of ovine preadipocytes. Differentiation was induced by the addition of insulin (1·6 g/ml), T 3 (2 nM) and lipid (10 l/ml) plus other additions as indicated; FGF 100 ng/ml; GH 45 ng/ml; for 'GH 72 h', GH was added for the first 72 h of the differentiation period. GPDH activity was determined after 10 days of differentiation. dexamethasone-induced increase in PPAR-concentration in sheep preadipocytes could explain the effects of dexamethasone and rosiglitazone on differentiation we have observed in these cells. The stimulatory effects of Excyte on differentiation may also be at least in part due to it acting as a source of fatty acid for the synthesis of natural ligands of PPAR-. A number of studies, mostly with rat cells, but also with human cells, have shown that preadipocytes from different depots vary in their ability to differentiate in response to an identical stimulus. Most of the studies with rat preadipocytes have involved comparison between epididymal and perirenal cells (Björntorp et al. 1980 , Wiederer & Löffler 1987 , Sztalryd et al. 1989 , Sztalryd & Faust 1990 , Kirkland et al. 1996 , Wabitsch et al. 1996b , while studies with subcutaneous preadipocytes are conflicting, with reports that subcutaneous preadipocytes differentiated better than (Grégoire et al. 1990 ), less well (Björntorp et al. 1980 , Sztalryd et al. 1991 or as well as epididymal preadipocytes (Lacasa et al. 1995 , Denis-Henriot et al. 1996 . The reasons for these differences are not clear. Studies with human preadipocytes (Hauner et al. 1988 , Adams et al. 1997 , however, showed that subcutaneous preadipocytes differentiated better than omental preadipocytes, as found in the present study. The present study also shows that the response of preadipocytes from different depots is influenced by the age of the donor animal and varies with the culture medium components, which could perhaps account for some of the differences found in previous studies with rat preadipocytes. It has been proposed that some apparent differences between preadipocytes from different depots could arise from variable contamination of preparations with non-preadipocyte cells. This would not appear to be a significant factor in the present studies as, when cells were cultivated with insulin, T 3 and rosiglitazone and dexamethasone, depot-specific differences mostly disappeared.
In sheep in vivo there is considerable hyperplasia of both abdominal and subcutaneous adipocytes during the foetal period, achieving about 10 9 subcutaneous and 5 10 8 omental and also perirenal adipocytes by birth (Vernon 1986) . Subsequently, there is further hyperplasia of subcutaneous preadipocytes during the suckling and fattening periods of development (Broad et al. 1980 , Vernon 1986 ). In contrast, postnatally, there is a little hyperplasia of abdominal preadipocytes during the suckling period, but very little subsequently (Broad et al. 1980 , Vernon 1986 ). This pattern of depot-specific, decreasing rates of hyperplasia seen in vivo is mimicked by the different amounts of differentiation achieved with preadipocytes in vitro in the present study, especially when using suboptimal combinations of factors. The bases of the depot-specific and also the age effects on preadipocyte differentiation are complex and not readily attributable to a single factor. However, some differences related to PPAR-would seem to be involved, as rosiglitazone is a common factor of the combinations which attenuate differences in differentiation. The more limited ability of omental preadipocytes, and adipocytes in general from older animals, to differentiate may be in part due to a more limited ability to produce the natural ligands for PPAR-, but other factors, perhaps the amount of PPAR-per cell, must also be involved.
